BioEclipse Therapeutics is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immuno-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique multi-mechanistic combination approach could address needs of patients with cancers that most think are not treatable. BioEclipse Therapeutics is preparing to initiate Phase 1b/2a clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX-100, is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers. BioEclipse Therapeutics is a resident company of Johnson & Johnson Innovation. JLABS, a premier life science incubator program.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/25/19 | $7,700,000 | Series A-1 |
DEFTA Partners Plum Alley Investments Revelis Capital Group  TEEC Angel Fund Tsingyuan Ventures | undisclosed |
